Video

Dr Malalur on the Implications of NALIRIFOX in Pancreatic Ductal Adenocarcinoma

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

Pannaga G. Malalur, MBBS, medical oncology specialist, Gastrointestinal Cancers, The Ohio State University Comprehensive Cancer Center (OSUCCC) - James Cancer Hospital & Solove Research Institute, discusses the implications of the findings for the use of liposomal irinotecan (Onivyde) plus 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma (PDAC)

The phase 3 NAPOLI 3 trial (NCT04083235) evaluated the NALIRIFOX regimen nab-paclitaxel (Abraxane) plus gemcitabine in this patient population. Findings presented at the 2023 Genitourinary Cancers Symposium showed a clinically meaningful and statistically significant improvement in both overall survival (OS) and progression-free survival (PFS) with NALIRIFOX. At a median follow-up of 16.1 months (95% CI, 15.3-16.8), a median OS of 11.1 months (95% CI, 10.0-12.1) was observed in the 383 patients treated with NALIRIFOX vs 9.2 months (95% CI, 8.3-10.6) for the 387 patients treated with nab-paclitaxel plus gemcitabine (HR, 0.83; 95% CI, 0.70-0.99; P = .04).

The median PFS was 7.4 months (95% CI, 6.0-7.7) and 5.6 months (95% CI, 5.3-5.8) for those treated with NALIRIFOX and nab-paclitaxel/gemcitabine, respectively (HR, 0.69; 95% CI, 0.58-0.83; P < .0001).

Although safety data from the study demonstrated similar rates of grade 3 or higher treatment-emergent adverse effects (TEAEs) between the NALIRIFOX arm (87%) and the nab-paclitaxel/gemcitabine arm (86%), the AEs observed with NALIRIFOX varied from what was seen with standard of care chemotherapy, Malalur says. For example, patients treated with NALIRIFOX experienced a higher rates of gastrointestinal TEAEs, including nausea, vomiting, and diarrhea, and those treated with nab-paclitaxel plus gemcitabine experienced more cytopenias, Malalur explains.

The efficacy and safety data point to NALIRIFOX as a potential new first-line treatment option for patients with metastatic PDAC, and the varying TEAEs associated with the regimen and nab-paclitaxel/gemcitabine could allow for different choices for patients in this setting, Malalur concludes.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma